8-K: Soligenix SGX945 Gets Orphan Drug Status for Behcet's Disease

Soligenix, Inc. announced that the FDA granted orphan drug designation to dusquetide (SGX945) for Behcet's Disease, providing seven years of market exclusivity upon approval.

Summary

• The United States Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation to dusquetide, the active ingredient in SGX945, for the treatment of Behcet's Disease.
• This designation follows a review of recent Phase 2a clinical results that demonstrated biological efficacy and safety in patients with Behcet's Disease.
• Orphan drug designation provides seven years of U.S. market exclusivity upon final FDA approval.
• The designation also positions the company to leverage financial and regulatory benefits, including government grants for clinical trials, waiver of FDA user fees for New Drug Application (NDA) submission, and certain tax credits.
• Behcet's Disease is a rare disorder affecting fewer than 200,000 people in the U.S., with approximately 18,000 known cases in the U.S., over 50,000 in Europe, and up to 1 million worldwide.
• A Phase 2a pilot study in 8 patients with Behcet's Disease showed SGX945 achieved a 40% improvement in the area under the curve (AUC) of the mean number of ulcers versus time after 4 weeks of treatment, compared to a 37% improvement for apremilast (Otezla) in its Phase 3 study.
• The improvement with SGX945 was sustained at Week 8 (32% improvement) despite treatment having stopped at Week 4.
• SGX945 was well-tolerated with no treatment-related adverse events observed.

Sentiment

Score: 9

Explanation: The granting of Orphan Drug Designation is a highly positive development for a biopharmaceutical company, providing significant market exclusivity and financial incentives. The positive Phase 2a data, particularly its favorable comparison to an already approved drug with a better safety profile, substantially enhances the drug's potential and the company's prospects in addressing an unmet medical need.

Positives

• Orphan Drug Designation granted for SGX945 in Behcet's Disease, a significant regulatory milestone.
• Provides seven years of U.S. market exclusivity upon FDA approval, enhancing future revenue potential.
• Qualifies for substantial financial and regulatory benefits, including government grants for clinical trials, waiver of expensive FDA user fees for NDA submission, and certain tax credits.
• Phase 2a clinical results demonstrated biological efficacy and safety in patients with Behcet's Disease.
• SGX945 showed a 40% improvement in oral ulcers after 4 weeks, outperforming apremilast's 37% improvement in its Phase 3 study using the same endpoint.
• The therapeutic effect of SGX945 was sustained for 4 weeks post-treatment (32% improvement at Week 8), indicating potential for lasting benefits.
• SGX945 was well-tolerated with no treatment-related adverse events, contrasting with apremilast's common side effects like diarrhea (41%), nausea (19%), and headache (14%).
• The company holds a strong intellectual property position in the Innate Defense Regulator (IDR) technology platform, including composition of matter for dusquetide.
• Dusquetide has also been awarded Fast-Track designation for the treatment of oral lesions of Behcet's Disease by the FDA.

Risks

• Actual results may differ materially from forward-looking statements due to risks and uncertainties beyond the company's control.
• Significant uncertainty is inherent in developing therapeutics and vaccines, conducting preclinical and clinical trials, obtaining regulatory approvals, and manufacturing.
• Product development and commercialization efforts may be reduced or discontinued due to difficulties or delays in clinical trials or lack of progress/positive results from research and development efforts.
• Inability to successfully obtain further funding to support product development and commercialization efforts, including grants and awards.
• Existing grants are subject to performance requirements and may not be maintained.
• Inability to enter into biodefense procurement contracts with the U.S. Government or other countries.
• Competition with larger and better financed competitors in the biotechnology industry.
• Changes in health care practice, third-party reimbursement limitations, and Federal and/or state health care reform initiatives could negatively affect the business.
• The U.S. Congress may not pass any legislation that would provide additional funding for the Project BioShield program.
• No assurance as to the timing or success of any clinical/preclinical trials.
• No assurance that the second HyBryte (SGX301) Phase 3 clinical trial will be successful or that a marketing authorization from the FDA or EMA will be granted.
• No assurance that the company will be able to modify the development path to adequately address the FDA's concerns regarding HyBryte (SGX301) or that the FDA will not require a longer duration comparative study.
• No assurance as to the timing or success of the clinical trials of SGX302 for the treatment of psoriasis.
• No assurance as to the timing or success of the clinical trials of SGX945 for the treatment of Behcet's Disease, despite the biologic activity observed.
• No assurance that RiVax will qualify for a biodefense Priority Review Voucher (PRV) or that prior sales of PRVs will be indicative of any potential sales price for a PRV for RiVax.
• No assurance that the company will receive or continue to receive non-dilutive government funding from grants and contracts.

Future Outlook

The company is hopeful that dusquetide will play a significant role in helping underserved patients suffering from Behcet's Disease. The FDA's orphan drug designation for SGX945 is considered an important step as the company continues to advance the program. Additionally, the company plans to seek worldwide regulatory approvals for HyBryte (SGX301) following the successful completion of its second Phase 3 study.

Management Comments

• "Given the clinically meaningful improvements seen in a Phase 2 proof-of-concept study in patients with oral aphthous ulcers due to Behcet's Disease, we are hopeful dusquetide will have a role to play in helping underserved patients suffering from this difficult to treat and chronic auto-immune disease." Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix.
• "The FDA's decision to grant orphan drug designation to the SGX945 program signifies an important step for Soligenix as we continue to advance the program and adds significantly to the existing intellectual property estate surrounding this novel technology." Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix.

Industry Context

Behcet's Disease is a rare, incurable inflammatory disorder of the blood vessels, primarily affecting young adults and causing painful symptoms like mouth sores, skin rashes, and eye inflammation. It represents a significant unmet medical need globally, with current treatments often involving corticosteroids or immunosuppressants that have limited long-term efficacy and notable side effects. Apremilast (Otezla) is the only FDA-approved drug for oral ulcers in Behcet's, but it requires continuous administration, is costly, and is associated with side effects. SGX945, as an innate defense regulator (IDR), offers a novel mechanism of action by modulating the body's immune response towards healing and anti-inflammation, without direct antibiotic activity. This distinct approach and its favorable safety profile demonstrated in Phase 2a position SGX945 as a potentially superior and much-needed therapeutic option in the rare disease market.

Comparison to Industry Standards

• SGX945's Phase 2a study for Behcet's Disease utilized the same primary endpoint (area under the curve of the mean number of ulcers versus time) as the published Phase 3 study for apremilast (Otezla), an approved drug for oral ulcers in Behcet's disease.
• After 4 weeks of treatment, the SGX945 treated group demonstrated a 40% improvement relative to the placebo group from the Phase 3 apremilast study.
• In contrast, apremilast, in its Phase 3 study, showed a 37% improvement relative to placebo.
• SGX945's improvement was sustained at Week 8 (32% improvement) even after treatment ceased at Week 4, indicating a durable effect.
• Apremilast, which was continuously administered through Week 12, showed a 41% improvement at Week 8.
• SGX945 was well-tolerated with no treatment-related adverse events reported.
• Common adverse events for apremilast included diarrhea (41% of patients), nausea (19% of patients), and headache (14% of patients), none of which were observed with SGX945.

Stakeholder Impact

• Shareholders: Positive impact due to enhanced drug pipeline value, potential for future revenue from market exclusivity, and reduced development costs through grants and fee waivers.
• Patients (Behcet's Disease): Potential for a new, effective, and better-tolerated treatment option for an incurable disease with significant unmet medical needs.
• Employees: Positive impact from progress in drug development and potential for future commercialization, contributing to job security and growth opportunities.

Next Steps

• Continue to advance the SGX945 program for Behcet's Disease.
• Seek regulatory approvals worldwide for HyBryte (SGX301) after successful completion of its second Phase 3 study.

Key Dates

Recommendation

The FDA's Orphan Drug Designation for SGX945 in Behcet's Disease is a pivotal positive development, significantly de-risking the drug's commercial pathway by granting 7 years of market exclusivity and providing substantial financial and regulatory benefits. The Phase 2a data, which demonstrates superior efficacy and a cleaner safety profile compared to the currently approved apremilast, suggests a strong competitive advantage. This news substantially enhances the company's long-term revenue potential and strengthens its intellectual property, making it a compelling investment opportunity for a seasoned investor.

Keywords

Biopharmaceutical, Orphan Drug, Behcet's Disease, SGX945, Dusquetide, FDA, Clinical Trials, Rare Disease, Innate Defense Regulator, SNGX, Drug Development, Market Exclusivity